Nautilus Biotechnology (NAUT) vs Revvity (RVTY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Revvity (RVTY) has outperformed Nautilus Biotechnology (NAUT) over the past year, gaining 47.8% versus a loss of 5.4%. Over five years, RVTY leads with a -20.7% price change compared with -56.4% for NAUT. Revvity is the larger company by market cap ($16.21 billion vs $270.0 million), about 60.0 times the size.
Revvity pays a dividend yielding 0.19%, while Nautilus Biotechnology does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | RVTY |
|---|---|---|
| Share price | $2.12 | $145.22 |
| Market cap | $270.03M | $16.21B |
| 1-day change | -2.30% | -4.20% |
| YTD return | +8.72% | +50.10% |
| 1-year return | -5.36% | +47.78% |
| 5-year return | -56.38% | -20.68% |
| P/E ratio (TTM) | — | 64.54 |
| Forward P/E | — | 24.38 |
| EPS (TTM) | $-0.46 | $2.25 |
| Dividend yield | 0.00% | 0.19% |
| Annual dividend | $0.00 | $0.28 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +3.67% |
| Net income (latest FY) | $-59.00M | $241.20M |
| Operating margin | — | 12.49% |
| Net margin | — | 8.45% |
| 52-week high | $4.31 | $171.74 |
| 52-week low | $0.841 | $81.22 |
| Distance from 52-week high | -50.81% | -15.44% |
| Analyst consensus | none | buy |
| Avg. price target upside | +88.68% | +18.03% |
| Average volume | 6.25M | 1.91M |
| Shares outstanding | 127.37M | 111.64M |
| Employees | 128 | 11,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revvity is about 60.0 times larger than Nautilus Biotechnology by market value ($16.21B vs $270.03M).
- RVTY has outperformed NAUT by 53.1 percentage points over the past year.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 128 employees
About Revvity
RVTY stock →Revvity, Inc. provides health sciences solutions, technologies, and services.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees
NAUT vs RVTY FAQ
Which is bigger, Nautilus Biotechnology or Revvity?
Revvity (RVTY) is larger, with a market capitalization of $16.21B compared with $270.03M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, NAUT or RVTY?
RVTY returned +47.78% over the past 12 months, compared with -5.36% for NAUT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Nautilus Biotechnology or Revvity?
Revvity pays a dividend yielding 0.19%, while Nautilus Biotechnology does not currently pay a regular dividend.
Are Nautilus Biotechnology and Revvity in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.